HEALTHCARE (XLV)

As of late February 2026, the financial narrative of the past two years has been dominated by a singular force in the healthcare sector: Eli Lilly & Company (NYSE: LLY). Once considered a traditional "Big Pharma" mainstay, Lilly has transcended its industry peers to become a high-octane growth engine, recently flirting

The company generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11.

Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’.

CASI stated the Nasdaq determined that the company had failed to satisfy the continued listing conditions to remain listed on the Nasdaq Stock Market.

The company’s board approved a 1-for-30 reverse stock split, effective on February 26.

The FDA has granted Breakthrough Therapy Designation to Larimar’s frataxin protein replacement therapy, nomlabofusp.

Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12.

The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, lifileucel and reported strong fourth-quarter earnings.

Baird analyst Catherine Ramsey Schulte slashed the price target on Grail to $82 from $113 while reiterating an ‘Outperform’ rating.

Intensity Therapeutics announced a 1-for-25 reverse stock split, consolidating every 25 existing shares into a single new share.

Immunic announced a private placement of up to $400 million to support its clinical studies and other operational needs.

Healthcare stocks have lagged the market for years, but 2026 is looking much better.

The acquisition will strengthen Lilly’s pipeline with a new class of therapies built on engineered circular RNA and proprietary lipid nanoparticles.

Invesco KBW Bank ETF tracks a benchmark of major U.S. banking institutions, offering targeted sector exposure and a moderate yield.

UnitedHealth expects some membership contraction in 2026 and noted that CMS’s Medicare rate “simply doesn't reflect the reality.”

Altimmune plans to raise $75 million via a direct offering to bankroll its Phase 3 MASH trial, easing near-term funding risk.

According to a Calcalist report, the company is set to go private after a $1.1 billion acquisition by a fund.

Stifel expects dip-buyers to step in, saying it would be surprised to see RVMD settle meaningfully below $100, calling the failed talks an “M&A clearing event.”

The healthcare landscape underwent a seismic shift in 2024, as the industry’s major players pivoted away from traditional hardware toward high-margin diagnostic platforms and artificial intelligence (AI)-integrated imaging software. This strategic realignment resulted in a massive $25.7 billion year-over-year jump in deal value for the diagnostics and

In the ROSELLA trial, patients receiving relacorilant with nab-paclitaxel saw their risk of death drop by about 35% compared with those given the chemotherapy alone.

ARK doubles down on a CRISPR bet as Intellia Therapeutics’ stock heads for its best week since October.

Heading to close this week as its best week since IPO, RGNT has become a retail favorite with surging followers on Stocktwits.